All News

AD109 reduced apnea-hypopnea index versus placebo in a phase 3 trial of adults with OSA unable or unwilling to use CPAP.

Takeda reported phase 3 data showing zasocitinib achieved higher week 16 PASI 100 responses than deucravacitinib in plaque psoriasis.

Late-breaking SLEEP 2026 findings bring primary-care-ready insights on insomnia drugs, sleep apnea genetics, menopausal sleep, and GLP-1 links.

SLEEP 2026: Women with moderate-to-severe obstructive sleep apnea reported worse sleep, fatigue, anxiety, headaches, and nocturia than men.

The first guideline for cardiovascular-kidney-metabolic syndrome details staging, screening, risk assessment, and treatment.

Xavier Llor, MD, of Yale Medicine, discusses what the updated guidance from the American Cancer Society on colorectal cancer screening mean for primary care.

Retatrutide phase 3 trials showed reductions in weight, A1C, osteoarthritis pain, and sleep apnea severity.

New FLOW trial data presented at ERA 2026 showed semaglutide improved health-related quality of life in adults with type 2 diabetes and CKD.

Recent FDA updates include new actions in diabetes, hypertension, chronic HDV infection, bipolar depression, and CKD in type 1 diabetes.

A national survey found US adults recognize STI transmission routes but remain uncertain about HPV and mpox vaccine prevention.

The FDA today issued a Complete Response Letter for Cingulate’s CTx-1301 for ADHD, citing CMC-related requests and no current safety or efficacy concerns.

FDA approved ensitrelvir for COVID-19 postexposure prophylaxis in adults and adolescents aged 12 years and older after exposure.

FDA approval expands Afrezza as an inhaled mealtime insulin option for pediatric patients with diabetes aged 6 years and older.

A national survey found high awareness of prenatal health guidance but gaps on alcohol avoidance, iron use, and gestational weight gain.

Post hoc phase 3 analyses linked centanafadine to improved executive function and emotional regulation in adults with ADHD.

ACS updated colorectal cancer screening guidance, reaffirming screening at age 45 and adding newer stool-based and blood-based options.

Kohli discusses the FDA approval of baxdrostat (Baxfendy), the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.

A validated AI phenotyping tool identified chronic long COVID burden missed by ICD surveillance in nearly 460,000 COVID-19 patients.